Novo Nordisk seeks U.S., European approval of diabetes drug

05/27/2008 | Bloomberg

Danish firm Novo Nordisk is seeking marketing approval for diabetes treatment liraglitude in the U.S. and Europe in a bid to launch the drug next year. Liraglitude is expected to compete with similar drugs being developed by Sanofi-Aventis and Novartis. The drug is based on glucagon-like peptide-1, a hormone that activates insulin production in the pancreas.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC